Andrew Cheng - Oct 2, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Oct 2, 2023
Transactions value $
-$1,038,827
Form type
4
Date filed
10/4/2023, 08:41 PM
Previous filing
Sep 25, 2023
Next filing
Dec 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $159K +25K +5.42% $6.36 486K Oct 2, 2023 Direct F1
transaction AKRO Common Stock Sale -$408K -8.87K -1.82% $46.06 477K Oct 2, 2023 Direct F1, F2
transaction AKRO Common Stock Sale -$248K -5.3K -1.11% $46.88 472K Oct 2, 2023 Direct F1, F3
transaction AKRO Common Stock Sale -$129K -2.66K -0.56% $48.56 469K Oct 2, 2023 Direct F1, F4
transaction AKRO Common Stock Sale -$84.5K -1.7K -0.36% $49.71 467K Oct 2, 2023 Direct F1, F5
transaction AKRO Common Stock Sale -$327K -6.47K -1.38% $50.56 461K Oct 2, 2023 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -25K -38.46% $0.00 40K Oct 2, 2023 Common Stock 25K $6.36 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.50 to $46.46, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.50, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.16 to $49.11, inclusive.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.17 to $50.05, inclusive.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.25 to $50.96, inclusive.
F7 The options are vested and currently exercisable.